Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies

NCT01527838 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT01527838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01527838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2012
Completion date
November 30, 2013
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all), acute myelogenous leukemia (aml), chronic lymphocytic leukemia (cll), hodgkin's disease, non-hodgkin's lymphoma (nhl)